VEDO - PREDIRESPUC project - Value of pharmacokinetic assays (Vedolizumab and anti-vedolizumab antibody) in the prediction of induction and maintenance therapeutic response in Ulcerative Colitis
Phase of Trial: Phase IV
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Acronyms PREDIRESPUC; VEDO-PREDIRESPUC
- 13 Sep 2019 Planned End Date changed from 20 Oct 2020 to 1 Sep 2022.
- 13 Sep 2019 Planned primary completion date changed from 30 Oct 2019 to 1 Sep 2021.
- 03 Jun 2019 New source identified and integrated ClinicalTrials.gov: US National Institutes of Health